CCO Treatment Updates
Doc Eye for the Hep Guy: Management of HCV Treatment-Experienced Patients
On-Demand Video Conference
Doc Eye for the Hep Guy: Management HCV Treatment–Experienced Patients
|
CME Program Director: Emmet B. Keeffe, MD, MACP
 
- Douglas T. Dieterich, MD
- Donald M. Jensen, MD
|
|
|
Douglas T. Dieterich, MD and Donald M. Jensen, MD, review the important issues of nonresponse and relapse in the treatment of chronic hepatitis C.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss definitions of response and nonresponse, methods of recognizing response, and factors involved in nonresponse
- Review recent data on treatment of HCV-infected patients who did not respond or relapsed after treatment
- Describe hematologic side effects of hepatitis C treatment and strategies for managing these side effects
|
CCO Slideset – Doc Eye for the Hep Guy: Management of HCV Treatment–Experienced Patients
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 1.36 MB
|
CCO Slidesets
Management of the HCV Therapy-Experienced Patient
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 895 KB
|
Treatment of HCV in Special Populations
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 779 KB
|
Management of Hematologic Side Effects to Optimize Response Rates to HCV Therapy
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 997 KB
|
Management of the HCV Therapy-Experienced Patient |
Module 1 of 4 |
|
CME Program Director: Emmet B. Keeffe, MD, MACP
|
|
Topics covered include:
- Introduction
- Characterizing Response in the Treatment-Experienced Patient
- Retreatment of the HCV Treatment-Experienced Patient
- Management of Patients Who Have Achieved SVR
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the recent data on treatment of HCV-infected patients who did not respond to or relapsed after treatment
- Describe interventions to reduce correctable factors that otherwise lead to dose reduction or discontinuation of therapy
- Review the different types of nonresponse and their implications for retrying therapy
|
Treatment of HCV in Special Populations |
Module 2 of 4 |
|
CME Program Director: Emmet B. Keeffe, MD, MACP
|
|
Topics covered include:
- Introduction
- Black Americans
- Clinical Trials
- Identifying Factors
- HCV/HIV Coinfection
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss recent data on treatment of hepatitis C in African American patients and the factors that lead to lower response rates in this population
- Describe treatment of hepatitis C in HIV-coinfected patients
- Review the impact of nonalcoholic fatty liver disease on the treatment of hepatitis C
|
Management of Hematologic Side Effects to Optimize Response Rates to HCV Therapy |
Module 3 of 4 |
|
CME Program Director: Emmet B. Keeffe, MD, MACP
|
|
Topics covered include:
- Introduction
- Neutropenia
- Thrombocytopenia
- Anemia
- Summary
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the spectrum of hematologic side effects caused by therapy for chronic hepatitis C.
- Discuss strategies for reducing and treating anemia due to ribavirin.
- Review approaches for addressing neutropenia and thrombocytopenia from therapy for chronic hepatitis C.
|
Entire Program in a Single Module: Doc Eye for the Hep Guy |
Module 4 of 4 |
|
CME Program Director: Emmet B. Keeffe, MD, MACP
 
- Donald M. Jensen, MD
- Mitchell L. Shiffman, MD
- Paul J. Pockros, MD
|
|
|
This program focuses on the issues faced by hepatitis-treating physicians in managing the complexities of hepatitis C patients and understanding new agents available for their treatment.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the recent data on treatment of HCV-infected patients who did not respond to or relapsed after treatment.
- Describe the hematologic side effects of hepatitis C treatment, and strategies for managing these side effects.
- Review treatment of challenging patient populations, including African Americans and HIV-coinfected patients.
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|